Get the Stockscreener App
0.84
4.18%
-0.0263
After Hours:
.82
-0.02
-2.38%
Heron Therapeutics Inc stock is traded at $0.84, with a volume of 2.14M.
It is down -4.18% in the last 24 hours and down -31.40% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$0.8663
Open:
$0.851
24h Volume:
2.14M
Relative Volume:
1.23
Market Cap:
$158.37M
Revenue:
$154.90M
Net Income/Loss:
$-20.20M
P/E Ratio:
-6.971
EPS:
-0.1205
Net Cash Flow:
$-27.91M
1W Performance:
-14.43%
1M Performance:
-31.40%
6M Performance:
-35.66%
1Y Performance:
-66.53%
1-Day Range:
$0.821
$0.86
1-Week Range:
$0.821
$0.97
52-Week Range:
$0.821
$2.61
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
0.84 | 169.16M | 154.90M | -20.20M | -27.91M | -0.1205 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.64 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.11 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.36 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.80 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.29 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Initiated | H.C. Wainwright | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Market Trends: Is Heron Therapeutics Inc stock technically oversold2026 Key Highlights & Daily Momentum Trading Reports - baoquankhu1.vn
Clearline Capital LP Increases Holdings in Heron Therapeutics, Inc. $HRTX - MarketBeat
Baker BROS. Advisors LP Purchases New Position in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
HRTX SEC FilingsHeron Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Citigroup Inc. Increases Stock Position in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron Therapeutics Signals Profitable Growth After Strong Quarter - TipRanks
Earnings Call Summary | Heron Therapeutics(HRTX.US) Q4 2025 Earnings Conference - 富途牛牛
HC Wainwright Has Negative Forecast for HRTX FY2026 Earnings - MarketBeat
What is Northland Securities' Forecast for HRTX Q1 Earnings? - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
HRTX Should I Buy - Intellectia AI
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2025 Earnings Call Transcript - Insider Monkey
What is HC Wainwright's Estimate for HRTX Q1 Earnings? - MarketBeat
HRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Heron (HRTX) Q4 2025 Earnings Call Transcript - AOL.com
Heron Therapeutics: Profitable Growth Outlook and Acute Care Momentum Underpin Buy Rating and $3 Target - TipRanks
Heron Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Heron Therapeutics outlines $173M–$183M 2026 sales targets amid acute care momentum and expanded commercial investment - MSN
Heron Therapeutics Q4 Earnings Call Highlights - MarketBeat
Heron Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:HRTX) 2026-02-26 - Seeking Alpha
Key facts: Heron Therapeutics projects $173-$183M revenue by 2026; ZYNRELEF adoption rises; credit facilities expanded - TradingView
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Heron Therapeutics, Inc. Provides Earnings Guidance for the Year 2026 - marketscreener.com
Earnings call transcript: Heron Therapeutics Q4 2025 reports strong growth By Investing.com - Investing.com Canada
Heron Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
HRTX: 2025 net revenue rose 7.4% to $154.9M, with strong Acute Care growth and positive EBITDA - TradingView
HERON THERAPEUTICS ($HRTX) Releases Q4 2025 Earnings - Quiver Quantitative
Heron Therapeutics: Q4 Earnings Snapshot - Citizen Tribune
Heron Therapeutics: Fourth Quarter Earnings Overview - Bitget
HERON THERAPEUTICS, INC. /DE/ SEC 10-K Report - TradingView
Heron Therapeutics Q4 revenue dips as Acute Care segment holds fort - TradingView
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results - The Manila Times
HRTX: 2025 net revenue rose 7.4% to $154.9M, driven by Acute Care growth and new CMS J-Codes - TradingView
Aug Sectors: Whats Heron Therapeutics Incs historical returnWeekly Profit Recap & Technical Pattern Based Signals - baoquankhu1.vn
Heron Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Heron Therapeutics, Inc. (HRTX) Stock Analysis: Exploring A Potential Upside Of 258.13% - DirectorsTalk Interviews
Heron Therapeutics, Inc. $HRTX Shares Acquired by JW Asset Management LLC - MarketBeat
Heron Therapeutics (HRTX) Expected to Announce Earnings on Thursday - MarketBeat
Aug EndMonth: What are JOFF Fintech Acquisition Corp Debt Equity Composite Unitss growth leversMarket Trend Report & Verified Entry Point Detection - baoquankhu1.vn
MSN Money - MSN
Heron: Near The Bottom Of A Trading Range Despite Positives (NASDAQ:HRTX) - Seeking Alpha
Clearline Capital reports 6.7% Heron Therapeutics stake (HRTX) - Stock Titan
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 - The Manila Times
Should I set a stop loss on Heron Therapeutics Inc.Dollar Strength & Entry Point Confirmation Signals - mfd.ru
Can Heron Therapeutics Inc. expand into new marketsWeekly Risk Report & Breakout Confirmation Trade Signals - mfd.ru
How does Heron Therapeutics Inc. compare to its peersJuly 2025 Weekly Recap & Community Consensus Trade Alerts - mfd.ru
How strong is Heron Therapeutics Inc. (AXD2) stock earnings growthJuly 2025 WrapUp & Safe Capital Growth Tips - mfd.ru
How resilient is Heron Therapeutics Inc. stock in market downturnsJuly 2025 Rallies & Free Accurate Trade Setup Notifications - mfd.ru
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Heron Therapeutics Inc Stock (HRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):